MedPage Today on MSN
CAR-T Immune Toxicity Linked to Non-Relapse Mortality Risk in Myeloma
Chimeric antigen receptor (CAR) T-cell therapy-associated immune-related adverse events (CirAEs) were associated with a high ...
MedPage Today on MSN
CAR7 gene therapy shows promise in T-cell ALL
The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...
Under healthy conditions, the intestinal epithelium fully renews itself every three to five days. Aging and exposure to ...
8don MSN
Autologous T cell therapy targeting multiple antigens shows promise in treating pancreatic cancer
A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...
This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Researchers have found a reliable way to grow helper T cells from stem cells, solving a major challenge in immune-based ...
The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...
Cipla partners with ImmunoAct to introduce India’s first CAR-T cell therapy in Africa, enhancing accessible cancer treatment ...
Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback